drugset / Trial / NCT02900157
Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, study of MEDI9090 to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of MEDI9090 in adult subjects with advanced solid tumors.
Timeline
- Start
- 2016-08-09
- Primary completion
- 2020-01-23
- Completion
- 2020-01-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MEDI9090 | Unknown | — | Intravenous |
| Background | Durvalumab | Monoclonal antibody | — | Intravenous |